| |
Linagliptin
|
Placebo
|
|---|
| |
(n = 5488)
|
(n = 3290)
|
|---|
|
Cardiac failure (narrow SMQ)*, n (%)
|
26 (0.5)
|
8 (0.2)
|
|
Acute pulmonary edema
|
1 (0.0)
|
1 (0.0)
|
|
Cardiac failure
|
6 (0.1)
|
2 (0.1)
|
|
Cardiac failure, acute
|
2 (0.0)
|
0 (0.0)
|
|
Cardiac failure, chronic
|
1 (0.0)
|
0 (0.0)
|
|
Cardiac failure, congestive
|
7 (0.1)
|
5 (0.2)
|
|
Cardiogenic shock
|
2 (0.0)
|
0 (0.0)
|
|
Cardiopulmonary failure
|
1 (0.0)
|
0 (0.0)
|
|
Left ventricular failure
|
6 (0.1)
|
0 (0.0)
|
|
Pulmonary edema
|
1 (0.0)
|
2 (0.1)
|
|
Right ventricular failure
|
1 (0.0)
|
0 (0.0)
|
-
MedDRA, Medical Dictionary for Regulatory Activities; SMQ, standardized MedDRA queries.
- Data are based on MedDRA version 16.0.
- *Heart failure data are a total of the narrow SMQ listed. Individual patients may have had >1 event.
